Search Results - "Hayashi, H H"

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment by Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., Mitsudomi, T., Nishio, K., Nakagawa, K.

“…The efficacy of programmed death-1 blockade in epidermal growth factor receptor gene (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) patients with…”
Get full text

Electrochemical recovery of Zr and Cd from molten chloride salts for reprocessing of used nitride fuels by Murakami, T., Hayashi, H.

“…Excess amounts of dissolution agents, CdCl2 and ZrCl4, are required to dissolve transuranium (TRU: Pu and minor actinides) nitrides into LiCl-KCl melts at the…”
Get full text

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary by Tanizaki, J., Yonemori, K., Akiyoshi, K., Minami, H., Ueda, H., Takiguchi, Y., Miura, Y., Segawa, Y., Takahashi, S., Iwamoto, Y., Kidera, Y., Fukuoka, K., Ito, A., Chiba, Y., Sakai, K., Nishio, K., Nakagawa, K., Hayashi, H.

“…Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a…”
Get full text

Drug-Induced Liver Injury Network Causality Assessment: Criteria and Experience in the United States by Hayashi, Paul H

“…Hepatotoxicity due to drugs, herbal or dietary supplements remains largely a clinical diagnosis based on meticulous history taking and exclusion of other…”
Get full text

Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi by Tanizaki, J., Nakagawa, K., Hayashi, H.

Get full text

Hepatic histological findings in suspected drug‐induced liver injury: Systematic evaluation and clinical associations by Kleiner, David E., Chalasani, Naga P., Lee, William M., Fontana, Robert J., Bonkovsky, Herbert L., Watkins, Paul B., Hayashi, Paul H., Davern, Timothy J., Navarro, Victor, Reddy, Rajender, Talwalkar, Jayant A., Stolz, Andrew, Gu, Jiezhun, Barnhart, Huiman, Hoofnagle, Jay H.

“…Drug‐induced liver injury (DILI) is considered to be a diagnosis of exclusion. Liver biopsy may contribute to diagnostic accuracy, but the histological…”
Get full text

Association between Decreased Social Participation and Depressive Symptom Onset among Community-Dwelling Older Adults: A Longitudinal Study during the COVID-19 Pandemic by Noguchi, Taiji, Hayashi, T., Kubo, Y., Tomiyama, N., Ochi, A., Hayashi, H.

“…Objectives The Coronavirus disease (COVID-19) pandemic has imposed restrictions on people’s social behavior. However, there is limited evidence regarding the…”
Get full text

Gastric functional monitoring by gastric electrical impedance tomography (gEIT) suit with dual-step fuzzy clustering by Sakai, K., Darma, P. N., Sejati, P. A., Wicaksono, R., Hayashi, H., Takei, M.

“…Gastric Function has been successfully estimated by gastric electrical impedance tomography ( g EIT) Suit with dual-step fuzzy clustering. The g EIT Suit which…”
Get full text

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer by Hayashi, H, Arao, T, Togashi, Y, Kato, H, Fujita, Y, De Velasco, M A, Kimura, H, Matsumoto, K, Tanaka, K, Okamoto, I, Ito, A, Yamada, Y, Nakagawa, K, Nishio, K

“…POU5F1B (POU domain class 5 transcription factor 1B), a processed pseudogene that is highly homologous to OCT4 , was recently shown to be transcribed in cancer…”
Get full text

Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report by Andrade, Raúl J., Aithal, Guruprasad P., de Boer, Ynto S., Liberal, Rodrigo, Gerbes, Alexander, Regev, Arie, Terziroli Beretta-Piccoli, Benedetta, Schramm, Christoph, Kleiner, David E., De Martin, Eleonora, Kullak-Ublick, Gerd A., Stirnimann, Guido, Devarbhavi, Harshad, Vierling, John M., Manns, Michael P., Sebode, Marcial, Londoño, Maria Carlota, Avigan, Mark, Robles-Diaz, Mercedes, García-Cortes, Miren, Atallah, Edmond, Heneghan, Michael, Chalasani, Naga, Trivedi, Palak J., Hayashi, Paul H., Taubert, Richard, Fontana, Robert J., Weber, Sabine, Oo, Ye Htun, Zen, Yoh, Licata, Anna, Lucena, M Isabel, Mieli-Vergani, Giorgina, Vergani, Diego, Björnsson, Einar S.

“…Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH)…”
Get full text

Death and liver transplantation within 2 years of onset of drug‐induced liver injury by Hayashi, Paul H., Rockey, Don C., Fontana, Robert J., Tillmann, Hans L., Kaplowitz, Neil, Barnhart, Huiman X., Gu, Jiezhan, Chalasani, Naga P., Reddy, K. Rajender, Sherker, Averell H., Hoofnagle, Jay H.

“…Drug‐induced liver injury (DILI) is an important cause of death and indication for liver transplantation (fatality). The role of DILI in these fatalities is…”
Get full text

Declining liver utilization for transplantation in the United States and the impact of donation after cardiac death by Orman, Eric S., Barritt, A. Sidney, Wheeler, Stephanie B., Hayashi, Paul H.

“…Worsening donor liver quality resulting in decreased organ utilization may be contributing to the recent decline in liver transplants nationally. We sought to…”
Get full text

Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury by Davern, Timothy J, Chalasani, Naga, Fontana, Robert J, Hayashi, Paul H, Protiva, Petr, Kleiner, David E, Engle, Ronald E, Nguyen, Hanh, Emerson, Suzanne U, Purcell, Robert H, Tillmann, Hans L, Gu, Jiezhun, Serrano, Jose, Hoofnagle, Jay H

“…Background & Aims The diagnosis of drug-induced liver injury relies on exclusion of other causes, including viral hepatitis A, B, and C. Hepatitis E virus…”
Get full text

S-1 as an option for second-line treatment of NSCLC. Is the ‘East Side Story’ applicable in the West? by Hayashi, H., Mitsudomi, T.

Get full text

Clinical application of amplicon-based next-generation sequencing to therapeutic decision making in lung cancer by Takeda, M., Sakai, K., Terashima, M., Kaneda, H., Hayashi, H., Tanaka, K., Okamoto, K., Takahama, T., Yoshida, T., Iwasa, T., Shimizu, T., Nonagase, Y., Kudo, K., Tomida, S., Mitsudomi, T., Saigo, K., Ito, A., Nakagawa, K., Nishio, K.

“…The clinical implementation of genomic profiling for lung cancer with high-throughput, multiplex tests is warranted to allow prioritization of appropriate…”
Get full text

Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib by Takegawa, N., Hayashi, H., Iizuka, N., Takahama, T., Ueda, H., Tanaka, K., Takeda, M., Nakagawa, K.

Get full text

Regulation of cytokinin biosynthesis, compartmentalization and translocation by Hirose, Naoya, Takei, Kentaro, Kuroha, Takeshi, Kamada-Nobusada, Tomoe, Hayashi, Hiroaki, Sakakibara, Hitoshi

“…Cytokinins, a group of mobile phytohormones, play an important role in plant growth and development, and their activity is finely controlled by environmental…”
Get full text

Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer by Hayashi, H, Ochiai, T, Shimada, H, Gunji, Y

“…Laparoscopy-assisted surgery with extraperigastric lymph node dissection for gastric cancers has been described, but the clinical benefits of these surgeries…”
Get full text

Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer by Hayashi, H., Okamoto, I., Morita, S., Taguri, M., Nakagawa, K.

“…Given the growing number of drugs available for non-small-cell lung cancer (NSCLC), an effect of first-line chemotherapy on overall survival (OS) might be…”
Get full text

The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease by Kim, Hannah P., Navarro, Victor, Zacks, Steven, Odin, Joseph, Kleiner, David E., Hayashi, Paul H.

“…Oxaliplatin is an alkylating agent given with fluorouracil and leucovorin as a mainstay adjuvant chemotherapy for stage III colorectal cancer (CRC). Liver…”
Get full text